Barclays Reinstates Overweight on Tarsus Pharmaceuticals, Announces $110 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 52.4%

Neg 0% Neu 52.4% Pos 0%

Barclays analyst Glen Santangelo reinstates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Overweight and announces $110 price target.